The Swiss pharmaceutical company Novartis has presented the results for the third quarter of 2023. Thus, net sales increased by twelve percent to $11.8 billion. Net income is $1.5 billion, an increase of 14 percent. These are the first quarterly figures announced by the pharmaceutical company without its spun-off...
The pharmaceutical service provider Vetter is investing over 230 million euros in a new production building at its Ravensburg site, which will house several commercial filling lines. With the completion of the 122-meter-long, 44-meter-wide and 32-meter-high shell, an important milestone has now been reached following...
Even though Roche's pharmaceuticals business with prescription medicines continues to grow, the company suffered declining overall sales in the first half of 2023 due to the expected drop in demand for Covid-19 products. Roche Group sales fell eight percent to CHF 29.8 billion. The appreciation of the Swiss franc...
Gerresheimer continues on its growth path and reports a good half-year result. Sales grew organically by around 17 percent excluding currency effects and reached €957 million. Following the successful realignment of the product mix, the company is clearly benefiting from global megatrends in the pharma and biotech...
Novartis has signed an agreement to acquire Chinook Therapeutics. Chinook Therapeutics is a Seattle-based biopharmaceutical company in clinical-stage development of two high-value drugs for rare, severe chronic kidney disease. Approval results for one of the compounds are expected in the fourth quarter of 2023. The...
GSK will buy Canadian-based biopharmaceutical company Bellus Health, investing $2 billion. The acquisition will give the U.K.-based pharmaceuticals company access to a cough medicine for the treatment of chronic cough (RCC for short). The drug is currently in Phase III clinical development with anticipated approval and...
Sandoz signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The investment is expected to be at least $400 million, supporting the company’s ambition to drive the future growth of its global biosimilars portfolio. This represents one of the largest-ever...
Gerresheimer achieved double-digit growth in sales and operating result in the financial year 2022. Sales increased organically by 16.2 percent to more than €1.8 billion, driven by all divisions. Operating profit grew organically by 10.2 percent to 338.4 million euros. Adjusted net profit for fiscal 2022 amounted to €...
Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi. The company warmly thanks Dr. Reed for his leadership over these last years. Since joining Sanofi in 2018, John has laid the foundation for the company’s R&D transformation. He...
Shrinking demand for tests and medicines to treat Covid-19 has left its mark on Roche's annual results. The bottom line saw net income fall six percent to 13.5 billion Swiss francs from 14.9 billion a year earlier. The Swiss pharmaceutical group posted sales of 63.3 billion Swiss francs in 2022. This represents an...
